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Measuring universal health coverage based on an index of 
effective coverage of health services in 204 countries and 
territories, 1990–2019: a systematic analysis for the Global 
Burden of Disease Study 2019
GBD 2019 Universal Health Coverage Collaborators*
Summary
Background Achieving universal health coverage (UHC) involves all people receiving the health services they need, of 
high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both 
countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and 
WHO’s Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is 
important for understanding whether health services are aligned with countries’ health profiles and are of sufficient 
quality to produce health gains for populations of all ages.
Methods Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC 
effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework 
developed through WHO’s GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing 
health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from 
reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention 
coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; 
outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of 
location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator 
relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and 
population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage 
index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current 
metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of 
UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective 
coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private 
expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion 
target—1 billion more people benefiting from UHC by 2023—we estimated additional population equivalents with 
UHC effective coverage from 2018 to 2023.
Findings Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 
44·2–47·5) in 1990 to 60·3 (58·7–61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 
95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, 
sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 
2·6% [1·9–3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 
2010–2019 relative to 1990–2010. Many countries showed lagging performance on effective coverage indicators for 
non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-
communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many 
health systems are not keeping pace with the rising non-communicable disease burden and associated population 
health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita 
(r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is 
potentially achievable relative to their health spending. Under maximum efficiency of translating health spending 
into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita 
(US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 
2018 to 2023, an estimated 388·9 million (358·6–421·3) more population equivalents would have UHC effective 
coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. 
Current projections point to an estimated 3·1 billion (3·0–3·2) population equivalents still lacking UHC effective 
coverage in 2023, with nearly a third (968·1 million [903·5–1040·3]) residing in south Asia.
Interpretation The present study demonstrates the utility of measuring effective coverage and its role in supporting 
improved health outcomes for all people—the ultimate goal of UHC and its achievement. Global ambitions to 
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accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable 
diseases occurs and countries can better translate health spending into improved performance. Focusing on effective 
coverage and accounting for the world’s evolving health needs lays the groundwork for better understanding how 
close—or how far—all populations are in benefiting from UHC.
Funding Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Research in context
Evidence before this study
Various approaches have been proposed for monitoring 
universal health coverage (UHC) service coverage, including 
those from WHO (ie, the UHC service coverage index, 
the official UN measure for the Sustainable Development Goal 
indicator 3.8.1) and the World Bank. Currently available service 
coverage metrics are heavily focused on infectious diseases as 
well as reproductive, neonatal, maternal, and child health, 
despite the recognition that advances towards UHC also 
require service provision for non-communicable diseases and 
delivering interventions to a broader range of population-age 
groups. Inconsistent trend estimation across indicators, 
if time series are generated, impedes measurements of 
progress—a priority emphasised in the member-state-led 
Political Declaration for the UN High-Level Meeting on 
Universal Health Coverage in 2019. Although the 2014 WHO 
and World Bank framework for UHC service coverage is 
explicitly focused on health-system effective coverage, 
efforts to date have focused on crude coverage or health-
system resource inputs, or a combination of both. Effective 
coverage at the health-system level, or the fraction of 
potential health gains delivered by a health system, has yet to 
be incorporated into UHC monitoring efforts, even though 
WHO and member states have signalled increasing interest in 
understanding the impact of UHC beyond service coverage 
alone.
Added value of this study
Drawing from the WHO Thirteenth General Programme of 
Work (GPW13) Expert Reference Group and Task Force on 
Metrics recommendations on UHC monitoring and conceptual 
work on effective coverage of health systems, the present 
study offers a new measurement framework for UHC effective 
coverage, representing health needs and corresponding 
service types across the life course while accounting for 
potential health gains delivered to populations. 
The framework mapped 23 effective coverage indicators 
against five health service domains—promotion, prevention, 
treatment, rehabilitation, and palliation—and five population-
age groups (ie, reproductive and newborn, children <5 years, 
children and adolescents aged 5–19 years, adults aged 
20–64 years, and adults aged ≥65 years). Based on estimates 
from the Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD) 2019, these 23 effective coverage indicators 
involved either direct measures of intervention coverage 
(eg, antiretroviral therapy coverage) or outcome-based 
indicators, such as mortality-to-incidence ratios, to approximate 
access to quality care. We weighted each effective coverage 
indicator on the basis of potential health gains deliverable by 
health systems, as approximated by the disability-adjusted 
life-years associated with each effective coverage indicator, 
and aggregated them to produce the UHC effective coverage 
index. Three types of validity were assessed (content, known 
groups, and convergent) for the UHC effective coverage index 
and other multi-country service coverage measures (eg, the UHC 
service coverage index for 2017, as estimated by WHO, and the 
GBD 2017 UHC service coverage index for 2017). We also 
quantified relationships between pooled health spending per 
capita (ie, government expenditures, prepaid private 
spending, and development assistance for health) and UHC 
effective coverage performance to examine how well 
countries are currently translating resources into improved 
UHC effective coverage. Last, we estimated the number of 
population equivalents covered by effective health services 
from 2018 to 2023—a key component of WHO’s GPW13—
by assuming a direct translation of the UHC effective coverage 
index to a fractional metric and multiplying country-level 
population estimates.
Implications of all the available evidence
This study offers another step forward in measuring UHC 
effective coverage across settings, developing a measurement 
framework and methods for country and global stakeholders 
to better track progress in effective health service provision at 
the population level. Our results highlight the importance of 
including non-communicable disease indicators alongside 
interventions for reproductive, neonatal, maternal, and child 
health and for infectious diseases, as well as capturing 
potential health gains delivered by health systems at the 
population level. In combination, we expect these analytical 
advances to better identify where countries have improved 
effective health service delivery, and what health needs along 
the life course increasingly threaten further progress. Focusing 
on UHC effective coverage, both in terms of its measurement 
and its capacity for instilling greater accountability for 
improving health outcomes across the development spectrum, 
lays a data-driven path towards achieving UHC for all 
populations.
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Introduction
Universal health coverage (UHC) is viewed as a crucial 
avenue through which improved health for all can be 
attained,1,2 by ensuring all people can receive quality 
health services they need, without experiencing financial 
hardship. Global agendas and actors have amplified calls 
for UHC in recent years, driven at least in part by the 
explicit inclusion of UHC achievement in target 3.8 of 
the UN Sustainable Development Goals (SDGs)3–5 and 
heightened emphasis within recent UN resolutions1 and 
WHO programmatic objectives (eg, the target of 1 billion 
more people benefiting from UHC from 2018 to 2023 as 
part of WHO’s Thirteenth General Programme of Work 
[GPW13]).6,7 Regional and country-driven efforts to elevate 
UHC on policy agendas have occurred as well, both 
building upon long estab lished UHC programmes (eg, in 
Japan,8 much of western Europe,9,10 and many countries 
in Latin America11,12) and galvanising newer commitments 
to UHC implementation (eg, in India, Kenya, and South 
Africa).13 To better understand how actions and investments 
are delivering on the ultimate goal of UHC—improving 
health outcomes—it is essential to quantify and track 
trends in effective health service provision, as well as the 
extent to which advances in service coverage correspond 
with the potential health gains populations should 
experience.
In 2014, WHO and the World Bank published a UHC 
measurement framework in which service coverage 
was defined as a spectrum of services—promotion, 
prevention, treatment, rehabilitation, and palliation—
across the life cycle.14,15 This framework emphasised 
the importance of providing services for individuals’ 
health needs throughout their lifespans and quantifying 
effective coverage of interventions delivered by health 
systems. Conceptually, effective coverage unites inter-
vention need, use, and quality into a single metric, 
representing the proportion of health gain that could 
be potentially received from an intervention relative to 
what is actually experienced.16,17 At the health-system 
level, effective coverage aims to capture the fraction of 
total potential health gains actually delivered relative to 
what a health system could have theoretically delivered.16 
To quantify such population-level health gains, Shengelia 
and colleagues outlined an approach to measure an 
aggregate of health-system effective coverage.16 Effective 
coverage is a powerful measure: this metric not only 
demands accountability of intervention availability and 
use, but also requires that the services received are of 
sufficient quality to provide the health gains they are 
supposed to. Yet in practice, effective coverage has to date 
been rarely measured, particularly across countries and 
over time. Minimal uptake of effective coverage as a 
metric for UHC monitoring is at least partly due to data 
challenges, as most health data systems are not able to 
capture all three intervention components together (ie, 
need, use or receipt, and quality) and few data sources 
can adequately represent these dimensions for conditions 
involving more complex care (eg, cancer or stroke). 
Tracer or proxy indicators of effective coverage exist for 
certain interventions or cause groups (eg, cancers), and 
recent health-system research by Kruk and colleagues 
used mortality-to-incidence rates to garner insights into 
health-care quality in low-income to middle-income 
countries.18 Nevertheless, to date no multi-country UHC 
measure ment effort to our knowledge has sought to 
estimate effective coverage across health service domains 
and population-age groups within a cohesive analytical 
platform.
Following the 2014 WHO/World Bank UHC monitoring 
framework and SDG adoption in 2015, several multi-
country health service coverage indices have been 
developed to inform UHC measurement.19–26 Although 
each effort has shown recognition of prevailing data 
limitations and challenges with operationalising UHC 
service coverage across myriad settings,21,24 they each have 
limitations in how well they capture country-level trends 
and health service needs across the life course.17,27–31 First, 
current indices primarily rely solely on household survey 
point estimates from multi-country survey series, which 
can lead to various measurement limitations (ie, being 
primarily focused on low-income to middle-income 
countries; restricted sets of interventions captured; and 
lags in data availability for understanding trends). 
Second, most indices include either risk factor indicators 
(eg, prevalence of non-smoking and non-raised blood 
pressure in the UHC service coverage index,19–21 the 
SDG indicator 3.8.14) or health-system inputs or process 
indicators (eg, health workers per capita and hospital 
beds per capita in the UHC service coverage index; 
inpatient admission rates for Wagstaff and colleagues’ 
service coverage index23,24), or both. The use of such proxy 
indicators, as well as those influenced by factors outside 
the health system (eg, tobacco prevalence), for service 
coverage measurement could misattribute successes in 
health service provision or misrepresent UHC service 
coverage. With non-communicable diseases accounting 
for at least 60% of early death and disability worldwide,32 
the omission of non-communicable disease indicators 
beyond risk factor prevalence proxies or cancer screening 
is at odds with the reality of countries’ populations and 
health systems. Third, approaches used to construct 
overall indices of UHC service coverage typically involve 
somewhat arbitrary weighting schemes (eg, a series of 
geometric means4,19–21 or weighted geometric means23,24), 
and thus might not capture the alignment of services 
provided given a country’s health and demographic 
profile. Last, none of these approaches explicitly accounts 
for the potential health gains delivered through the 
health system, a limitation that inhibits our collective 
understanding of whether or how gains in UHC are 
improving health outcomes for all.
Recent developments from WHO indicate a revived 
interest in using effective coverage for UHC monitoring; 
these include the WHO GPW13 Expert Reference Group 
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(ERG) Task Force on Metrics recommendations on 
effective service coverage measurement33 and the WHA72 
resolution recommending country pilots on monitoring 
UHC effective coverage.7 The GPW13 ERG also supported 
initial efforts to map health services against population-
age groups within a measurement framework and to 
identify indicator options across the life course in order to 
estimate UHC effective coverage across countries.33 The 
present analysis contributes to this endeavour through 
the Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD) 2019, mapping 23 effective coverage indi-
cators across health service types and population-age 
groups for 204 countries and territories from 1990 to 2019. 
Based on the construct of health-system effective coverage, 
we aggregated individual effective coverage indicators 
to produce an overall index using health gain weights, 
which were derived from country-specific disease burden 
estimates relative to theoretical levels of burden avertable 
given intervention levels and associated effectiveness. We 
compared the performance of this UHC effective coverage 
measure against that of previous multi-country UHC 
service coverage indices21,24,26 on a series of validity tests. We 
then assessed the relationships between pooled health 
spending per capita and index performance, aiming to 
capture how close—or how far—countries were in 
reaching UHC effective coverage frontiers relative to their 
current spending. Finally, we considered applications of 
this index for current global and national UHC priorities, 
such as translating index performance to the number of 
people covered by effective coverage for the GPW13 UHC 
billion target.
Methods
Overview
Our primary analysis involved three main steps: first, to 
use intervention coverage or compute proxy measures of 
effective coverage for 23 indicators; second, to calculate 
the fraction of potential health gains associated with 
each effective coverage indicator based on each location’s 
disease burden profile; and third, to construct the overall 
UHC effective coverage index by weighting each effective 
coverage indicator relative to its health gains fraction. 
We then did secondary analyses, assessing UHC effec-
tive coverage performance relative to health spending 
and current trajectories towards the GPW13 UHC billion 
target. Each step is summarised below and further 
described in appendix 1 (pp 12–61).
This analysis uses estimates from the broader 
GBD 2019,34–36 covering 204 countries and territories from 
1990 to 2019. Details of disease-specific, injury-specific, 
and coverage-specific data inputs and processing, statis-
tical synthesis approaches, and final models are available 
in the accompanying GBD 2019 capstone publications.34–36 
This study complies with the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER) 
statement,37 with further information provided in the 
appendix 1 (pp 69–72).
Measurement of UHC effective coverage
Framework and indicators
Development of the UHC effective coverage measure-
ment framework and selection of effective coverage 
indicators was based on consultation, methods testing, 
and refinement via the WHO ERG on the GPW13 
from 2017 to 2019;7,33,38,39 the background and details of 
this process are provided in the appendix 1 (pp 12–28). 
The resulting framework (figure 1) and currently 
included effective coverage indicators (table 1) sought to 
represent the range of different health services that 
populations need across their lifespans while recog-
nising present data gaps and appeals for measurement 
parsimony (appendix 1 pp 18–28).
As applied in this analysis, the UHC effective coverage 
measurement framework involves 30 unique cells 
from a matrix of five health service types—promotion, 
prevention, treatment, rehabilitation, and palliation—
against five population-age groups (reproductive and 
newborn, children younger than 5 years, children and 
adolescents aged 5–19 years, adults aged 20–64 years, 
and older adults aged ≥65 years). Treatment is sub-
divided into two separate groups: first, communicable 
diseases and maternal, newborn, and child health; and 
second, non-communicable diseases. Effective coverage 
indica tors were then mapped to these cells to represent 
needed health services across the life course.
23 effective coverage indicators were included in the 
present analysis (table 1). As recognised in previous 
studies,19–26 data for directly measuring effective inter-
vention coverage are rarely available across health services, 
locations, and over time. Subsequently, we used viable 
proxy measures and analytical techniques to approximate 
effective coverage for conditions considered amenable to 
health care.40–43 Criteria set forth by the WHO ERG guided 
selection of effective coverage indica tors and preferred 
measurement approaches (appendix 1 pp 12–28).33 Such 
criteria stipulated that effective coverage indicators should 
be currently measurable (ie, data and methods that 
support indicator measurement today); reflect differences 
in effective health services and not factors outside the 
immediate scope of health systems and UHC (eg, tobacco 
taxation and physical infrastructure such as roads and 
water systems); and use indicators already encompassed 
within the SDGs and GPW13, or draw from data systems 
required for monitoring of SDGs and GPW13. Several 
other indicator candidates were considered from 2017 
to 2019 (appendix 1 pp 12–28), but inadequate data avail-
ability, access, or quality, or a combination of these factors, 
impeded their inclusion in the current analysis.
Four effective coverage indicators were measures 
of intervention coverage and 19 were mortality-based 
measures to proxy access to quality of care (table 1; 
appendix 1 pp 30–32). For the mortality-based measures, 
we primarily used mortality-to-incidence ratios (MIRs) 
and mortality-to-prevalence ratios (MPRs) for chronic or 
longer-term conditions (eg, diabetes or asthma). Without 
See Online for appendix 1
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better data on effective coverage, such mortality-based 
measures are viewed as suitable proxies,33,44–46 providing 
good signals on what access to quality care should, at 
minimum, avert or protect against even if the onset of 
disease cannot be wholly prevented. The main exception 
was ischaemic heart disease, for which GBD input data 
coverage and quality on non-fatal outcomes were less 
robust than data on causes of death and related risks; 
subsequently, we used risk-standardised death rates 
instead of MIRs or MPRs to proxy effective coverage. As 
a statistical approach used in previous GBD analyses41,43 
and further described in the appendix 1 (pp 31–32), 
risk standardisation aims to better isolate variations in 
mortality associated with health-care access and quality 
from differences in underlying risk exposures mainly 
related to factors outside the health system.
Effective coverage indicators for intervention coverage 
were kept on their natural scale (0–100%), whereas the 
19 other effective coverage indicators were transformed 
to values on a 0–100 scale (appendix pp 31–33). Across 
locations and from 1990 to 2019, 0 was set by values at 
the 97·5th percentile or higher (ie, “worst” levels of 
MIRs) and 100 by the 2·5th percentile or lower (ie, “best” 
levels of MIRs).
Figure 1: UHC effective coverage measurement framework
Additional information about the framework development process and selection of effective coverage indicators can be found in appendix 1 (pp 12–28). 
ART=antiretroviral therapy. DTP3=diphtheria-tetanus-pertussis vaccine, 3 doses. IHD=ischaemic heart disease. CKD=chronic kidney disease. COPD=chronic obstructive 
pulmonary disease. LRI=lower respiratory infection. MCV1=measles-containing-vaccine, 1 dose. MNCH=maternal, neonatal, and child health. NCDs=non-communicable 
diseases. TB=tuberculosis. UHC=universal health coverage.
Health service type
Population age group Promotion Prevention Treatment Rehabilitation Palliation
Communicable diseases and MNCH NCDs
Reproductive and 
newborn
Met need for 
family planning 
with modern 
contraception
Antenatal, 
peripartum, and 
postnatal care for 
newborn babies 
Antenatal, 
peripartum, and 
postnatal care for 
mothers
Antenatal, peripartum, and 
postnatal care for newborn 
babies 
Antenatal, peripartum, and 
postnatal care for mothers
Children younger 
than 5 years
Children and 
adolescents 
(5–19 years)
Adults 
(20–64 years)
Older adults 
(≥65 years)
DTP3 coverage 
MCV1 coverage
LRI treatment
Diarrhoea treatment
Acute lymphoid leukaemia 
treatment
ART coverage Acute lymphoid leukaemia 
treatment
Asthma treatment
Epilepsy treatment
Appendicitis treatment
Paralytic ileus and intestinal 
obstruction treatment
ART coverage
TB treatment
ART coverage
TB treatment
Diabetes treatment
IHD treatment
Stroke treatment
CKD treatment
COPD treatment
Cervical cancer treatment
Breast cancer treatment
Uterine cancer treatment
Colon and rectum cancer 
treatment
Epilepsy treatment
Appendicitis treatment
Paralytic ileus and intestinal 
obstruction treatment
Diabetes treatment
IHD treatment
Stroke treatment
CKD treatment
COPD treatment
Cervical cancer treatment
Breast cancer treatment
Uterine cancer treatment
Colon and rectum cancer 
treatment
Epilepsy treatment
Appendicitis treatment
Paralytic ileus and intestinal 
obstruction treatment
Global Health Metrics
www.thelancet.com   Vol 396   October 17, 2020 1255
Effective coverage 
indicator
Metric Effective coverage indicator measurement Health gain weight inputs Effectiveness 
category
Numerator Denominator
Reproductive and newborn
Promotion Met need for family 
planning with modern 
contraception
Coverage Females aged 15–49 years with 
demand for family planning met 
with modern contraception
Females aged 15–49 years with 
demand for family planning
50% of DALYs due to maternal 
disorders for females aged 
10–54 years
5
Prevention; 
treatment, 
communicable 
diseases and MNCH
Antenatal, peripartum, 
and postnatal care for 
newborn babies
Early 
neonatal 
mortality rate
All-cause deaths during the 
first 7 days of life
Population of early neonates Early neonatal deaths multiplied 
by life expectancy at birth (on the 
basis of theoretical minimum risk 
life table)
3
Prevention; 
treatment, 
communicable 
diseases and MNCH
Antenatal, peripartum, 
and postnatal care for 
mothers
Maternal 
mortality 
ratio
Deaths due to maternal disorders for 
females aged 10–54 years 
Livebirths among females aged 
10–54 years
50% of DALYs due to maternal 
disorders for females aged 
10–54 years
1
Children younger than 5 years
Prevention DTP3 vaccine coverage Coverage Receipt of three doses of DTP 
vaccine among children aged 
12–23 months
Children aged 12–23 months DALYs due to diphtheria, tetanus, 
and pertussis for children younger 
than 5 years
1
Prevention MCV1 coverage Coverage Receipt of MCV1 among children 
aged 12–23 months
Children aged 12–23 months DALYs due to measles for children 
younger than 5 years
1
Treatment, 
communicable 
diseases and MNCH
LRI treatment MIR Mortality from LRIs for children 
younger than 5 years
Incidence of LRIs for children 
younger than 5 years
DALYs due to LRIs for children 
younger than 5 years
1
Treatment, 
communicable 
diseases and MNCH
Diarrhoea treatment MIR Mortality from diarrhoeal diseases 
for children younger than 5 years
Incidence of diarrhoeal diseases 
for children younger than 5 years
DALYs due to diarrhoeal diseases 
for children younger than 5 years
1
Treatment, NCDs Acute lymphoid 
leukaemia treatment
MIR Mortality from acute lymphoid 
leukaemia for children aged 
1–4 years
Incidence of acute lymphoid 
leukaemia for children aged 
1–4 years
DALYs due to acute lymphoid 
leukaemia for children aged 
1–4 years
1
Children and adolescents (5–19 years)
Treatment, 
communicable 
diseases and MNCH
ART coverage Coverage Populations aged 5–19 years living 
with HIV/AIDS and on ART
Populations aged 5–19 years 
living with HIV/AIDS
DALYs due to HIV for populations 
aged 5–19 years
1
Treatment, NCDs Acute lymphoid 
leukaemia treatment
MIR Mortality from acute lymphoid 
leukaemia for populations aged 
5–19 years
Incidence of acute lymphoid 
leukaemia for populations aged 
5–19 years
DALYs due to acute lymphoid 
leukaemia for populations 
5–19 years
1
Treatment, NCDs Asthma treatment MPR Mortality from asthma for 
populations aged 5–19 years
Prevalence of asthma for 
populations aged 5–19 years
DALYs due to asthma for 
populations aged 5–19 years
1
Treatment, NCDs Epilepsy treatment MPR Mortality from epilepsy for 
populations aged 5–19 years
Prevalence of epilepsy for 
populations aged 5–19
DALYs due to epilepsy for 
populations aged 5–19 years
3
Treatment, NCDs Appendicitis treatment MIR Mortality from appendicitis for 
populations aged 5–19 years
Incidence of appendicitis for 
populations aged 5–19 years
DALYs due to appendicitis for 
populations aged 5–19 years
1
Treatment, NCDs Paralytic ileus and 
intestinal obstruction 
treatment
MIR Mortality from paralytic ileus and 
intestinal obstruction for 
populations aged 5–19 years
Incidence of paralytic ileus and 
intestinal obstruction for 
populations aged 5–19 years
DALYs due to paralytic ileus and 
intestinal obstruction for 
populations aged 5–19 years
1
Adults (20–64 years)
Treatment, 
communicable 
diseases and MNCH
ART coverage Coverage Population aged 20–64 years living 
with HIV/AIDS and on ART
Population aged 20–64 years 
living with HIV/AIDS
DALYs due to HIV for populations 
aged 20–64 years
1
Treatment, 
communicable 
diseases and MNCH
Tuberculosis treatment MIR Mortality from tuberculosis for 
populations aged 20–64 years
Incidence of tuberculosis for 
populations aged 20–64 years
DALYs due to tuberculosis for 
populations aged 20–64 years
1
Treatment, NCDs Diabetes treatment MPR Mortality from diabetes for 
populations aged 20–64 years
Prevalence of diabetes for 
populations aged 20–64 years
DALYs due to diabetes for 
populations aged 20–64 years
3
Treatment, NCDs IHD treatment RSDR Risk-standardised deaths from IHD 
for populations aged 20–64 years
Population aged 20–64 years DALYs due to IHD for 
populations aged 20–64 years
2
Treatment, NCDs Stroke treatment MIR Mortality from stroke for 
populations aged 20–64 years
Incidence of stroke for 
populations aged 20–64 years
DALYs due to stroke for 
populations aged 20–64 years
2
Treatment, NCDs CKD treatment MPR Mortality from CKD for 
populations aged 20–64 years
Incidence of CKD for 
populations aged 20–64 years
DALYs due to CKD for 
populations aged 20–64 years
1
(Table 1 continues on next page)
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Effective coverage 
indicator
Metric Effective coverage indicator measurement Health gain weight inputs Effectiveness 
category
Numerator Denominator
(Continued from previous page)
Treatment, NCDs COPD treatment MPR Mortality from COPD for 
populations aged 20–64 years
Prevalence of COPD for 
populations aged 20–64 years
DALYs due to COPD for 
populations aged 20–64 years
3
Treatment, NCDs Cervical cancer 
treatment
MIR Mortality from cervical cancer for 
females aged 20–64 years
Incidence of cervical cancer for 
females aged 20–64 years
DALYs due to cervical cancer for 
females aged 20–64 years
1
Treatment, NCDs Breast cancer treatment MIR Mortality from breast cancer for 
females aged 20–64 years
Incidence of breast cancer for 
females aged 20–64 years
DALYs due to breast cancer for 
females aged 20–64 years
1
Treatment, NCDs Uterine cancer 
treatment
MIR Mortality from uterine cancer for 
females aged 20–64 years
Incidence of uterine cancer for 
females aged 20–64 years
DALYs due to uterine cancer for 
females aged 20–64 years
1
Treatment, NCDs Colon/rectum cancer 
treatment
MIR Mortality from colon/rectum 
cancer for populations aged 
20–64 years
Incidence of colon/rectum for 
populations aged 20–64 years
DALYs due to colon/rectum 
cancer for populations aged 
20–64 years
1
Treatment, NCDs Epilepsy treatment MPR Mortality from epilepsy for 
populations aged 20–64 years
Prevalence of epilepsy for 
populations aged 20–64 years
DALYs due to epilepsy for 
populations aged 20–64 years
3
Treatment, NCDs Appendicitis treatment MIR Mortality from appendicitis for 
populations aged 20–64 years
Incidence of appendicitis for 
populations aged 20–64 years
DALYs due to appendicitis for 
populations aged 20–64 years
1
Treatment, NCDs Paralytic ileus and 
intestinal obstruction 
treatment
MIR Mortality from paralytic ileus and 
intestinal obstruction for 
populations aged 20–64 years
Incidence of paralytic ileus and 
intestinal obstruction for 
populations aged 20–64 years
DALYs due to paralytic ileus and 
intestinal obstruction for 
populations aged 20–64 years
1
Older adults (≥65 years)
Treatment, 
communicable 
diseases and MNCH
ART coverage Coverage Population aged ≥65 years living 
with HIV/AIDS and on ART
Population aged ≥65 years 
living with HIV/AIDS
DALYs due to HIV for populations 
aged ≥65 years
2
Treatment, 
communicable 
diseases and MNCH
Tuberculosis treatment MIR Mortality from tuberculosis for 
populations aged ≥65 years
Incidence of tuberculosis for 
populations aged ≥65 years
DALYs due to tuberculosis for 
populations aged ≥65 years
2
Treatment, NCDs Diabetes treatment MPR Mortality from diabetes for 
populations aged ≥65 years
Prevalence of diabetes for 
populations aged ≥65 years
DALYs due to diabetes for 
populations aged ≥65 years
4
Treatment, NCDs IHD treatment RSDR Risk-standardised deaths from IHD 
for populations aged ≥65 years
Population aged ≥65 years DALYs due to IHD for 
populations aged ≥65 years
3
Treatment, NCDs Stroke treatment MIR Mortality from stroke for 
populations aged ≥65 years
Incidence of stroke for 
populations aged ≥65 years
DALYs due to stroke for 
populations aged ≥65 years
3
Treatment, NCDs CKD treatment MPR Mortality from CKD for 
populations aged ≥65 years
Incidence of CKD for 
populations aged ≥65 years
DALYs due to CKD for 
populations aged ≥65 years
2
Treatment, NCDs COPD treatment MPR Mortality from COPD for 
populations aged ≥65 years
Prevalence of COPD for 
populations aged ≥65 years
DALYs due to COPD for 
populations aged ≥65 years
4
Treatment, NCDs Cervical cancer 
treatment
MIR Mortality from cervical cancer for 
females aged ≥65 years
Incidence of cervical cancer for 
females aged ≥65 years
DALYs due to cervical cancer for 
females aged ≥65 years
2
Treatment, NCDs Breast cancer 
treatment
MIR Mortality from breast cancer for 
females aged ≥65 years
Incidence of breast cancer for 
females aged ≥65 years
DALYs due to breast cancer for 
females aged ≥65 years
2
Treatment, NCDs Uterine cancer 
treatment
MIR Mortality from uterine cancer for 
females aged ≥65 years
Incidence of uterine cancer for 
females aged ≥65 years
DALYs due to uterine cancer for 
females aged ≥65 years
2
Treatment, NCDs Colon/rectum cancer 
treatment
MIR Mortality from colon/rectum 
cancer for populations aged 
≥65 years
Incidence of colon/rectum 
cancer for populations aged 
≥65 years
DALYs due to colon/rectum 
cancer for populations aged 
≥65 years
2
Treatment, NCDs Epilepsy treatment MPR Mortality from epilepsy for 
populations aged ≥65 years
Prevalence of epilepsy for 
populations aged ≥65 years
DALYs due to epilepsy for 
populations aged ≥65 years
4
Treatment, NCDs Appendicitis treatment MIR Mortality from appendicitis for 
populations aged ≥65 years
Incidence of appendicitis for 
populations aged ≥65 years
DALYs due to appendicitis for 
populations aged ≥65 years
2
Treatment, NCDs Paralytic ileus and 
intestinal obstruction 
treatment
MIR Mortality from paralytic ileus and 
intestinal obstruction for 
populations aged ≥65 years
Incidence of paralytic ileus and 
intestinal obstruction for 
populations aged ≥65 years
DALYs due to paralytic ileus and 
intestinal obstruction for 
populations aged ≥65 years
2
Additional information about the framework development process and selection of effective coverage indicators can be found in appendix 1 (pp 12–28). UHC=universal health coverage. DALYs=disability-
adjusted life-years. MNCH=maternal, neonatal, and child health. DTP3=diphtheria-tetanus-pertussis vaccine, 3 doses. MCV1=measles-containing-vaccine, 1 dose. LRI=lower respiratory infection. 
MIR=mortality-to-incidence ratio. NCDs=non-communicable diseases. ART=antiretroviral therapy. MPR=mortality-to-prevalence ratio. IHD=ischaemic heart disease. RSDR=risk-standardised death rate. 
CKD=chronic kidney disease. COPD=chronic obstructive pulmonary disease.
Table 1: Details of the 23 effective coverage indicators included in the UHC effective coverage index, by health service type
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Construction of UHC effective coverage index
As outlined by previous work,14–17 population-level measures 
of effective coverage should represent the fraction of total 
health gains a health system could potentially provide, 
given currently available interventions, that a health 
system actually delivers. This construct is thus grounded 
in the principle of comparability—all health systems ought 
to maximise potential health gains for their populations—
but also requires accounting for local health needs and 
epidemiological profiles. For instance, if a country 
currently experiences a high burden of diabetes and a 
comparatively lower burden of HIV, at least equal or even 
higher priority in expanding services for diabetes should 
occur relative to HIV in order to further support health 
gains.
To construct the UHC effective coverage index, we 
weighted each effective coverage indicator relative to 
their health gain weights, a metric approximating the 
population health gains potentially deliverable by 
health systems for each location-year. More detail is 
provided in the appendix 1 (pp 32–35), but in brief, 
calculations were based on three inputs for each 
effective coverage indicator and corresponding pop-
ulation-age group: estimates on the 0–100 scale, tar-
geted disease burden, and effectiveness categories of 
associated interventions or services (table 1). For effec-
tiveness, incremental values were assumed by category 
(ie, 90% effectiveness for category 1, 70% for category 2, 
50% for category 3, and so on), as informed by studies 
published in the Cochrane Database of Systematic 
Reviews, the Tufts Cost-Effectiveness Analysis Registry 
and Global Health Cost-Effectiveness Analysis Registry, 
and Disease Control Priorities, third edition (DCP3); 
sensitivity analyses on shifting each effective coverage 
indicator by one category (ie, moving each category 2 
indicator up to category 1 and then down to category 3) 
showed high correlations with current assignments 
(appendix 1 p 35).
As shown in figure 2, UHC effective coverage index 
estimates based on health gain weighting and an 
unweighted average across effective coverage indicators 
were positively associated (r=0·95); however, effects 
differed across countries.
Validation
Since no gold-standard measures of UHC service 
coverage currently exist, we used three types of validity 
testing to compare UHC effective coverage index perfor-
mance to previously published multi-country indices of 
UHC service coverage: the WHO UHC service coverage 
index for 2017;21 UHC service coverage index from 
GBD 2017;26 and service coverage index values from 
the World Bank.24 Further details of these analyses are 
provided in the appendix 1 (pp 38–52), with results 
summarised in table 2.
For content validity, we computed the percentage 
of 30 cells (ie, combinations of health services and 
population-age groups) from the UHC effective 
coverage framework that were represented by indi-
cators for each index. For known-groups validity, we 
assessed how well each index could discriminate 
between 16 country-pairs for which previous studies 
show “country A” as having better performance or 
progress on UHC service coverage than a similar 
“country B”.11,23,47–55 These pairs were selected a priori, 
and for each index we calculated the fraction of pairs 
correctly ordered on the basis of mean estimates 
and accounting for uncertainty where available. For 
convergent validity, we quantified how much variation 
in healthy life expectancy could be explained by each 
index after removing the average relationship between 
each index and overall socio demographic development 
(as measured by Socio-demographic Index [SDI]). In 
general, the UHC effective coverage index based on 
health gain weights showed stronger performance 
across these three validity mea sures than previous 
UHC service coverage measures and the unweighted 
UHC effective coverage index (table 2; appendix 1 
pp 38–52).
Figure 2: Comparing the UHC effective coverage index in 2019 with health gains weighting to the 
unweighted index (unweighted average of effective coverage indicators) in 2019
Locations are colour-coded by GBD super-region, and are abbreviated according to their ISO3 codes. ISO3 codes 
and corresponding location names are listed in appendix 1 (pp 64–68). UHC=universal health coverage. 
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
CHN
LAO
MDV
PHL
LKA
THA
FJI
KIR
FSM
PNG
SLB
VUT
AZE
KAZ
MNG
TKM
UZB
BIH
HUN
MKD
MNE
SRB
SVK
SVN
BLR
EST
RUS
UKR
JPN
KOR
SGP
AUTDNK
GRC
NOR
PRT
CHE
BLZ
GRD
GUY
VCT
PER
BRA
MAR
QAT
CAF
BDI
ETH
KEN
MWI
MOZ
RWA
SOM
UGA
BWA
LSO
NAM
ZAF
ZWE
CPV
TCD
GMB
GHA
GIN
GNB
STP
SEN
SLE PLW
PRI
TUV
VIR
20
40
60
80
100
20 40 60 80 100
UHC effective coverage index, unweighted average
UH
C 
eff
ec
tiv
e 
co
ve
ra
ge
 in
de
x,
 h
ea
lth
 g
ai
ns
 w
ei
gh
te
d
GBD super-region
Central Europe, eastern Europe, and central Asia
High income
Latin America and Caribbean
North Africa and Middle East
South Asia
Southeast Asia, east Asia, and Oceania
Sub-Saharan Africa
For the Cochrane Database of 
Systematic Reviews see 
https://www.cochranelibrary.
com/cdsr/reviews
For the Tufts Cost-Effectiveness 
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https://cevr.tuftsmedicalcenter.
org/databases/cea-registry
For the Global Health Cost-
Effectiveness Analysis Registry 
see https://ghcearegistry.org/
ghcearegistry/
For more on Disease Control 
Priorities, third edition see 
https://dcp-3.org/
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Relationship between health spending and UHC 
effective coverage
To better understand potential drivers of UHC effective 
coverage, we used stochastic frontier metaregression 
to quantify UHC effective coverage frontiers—esti-
mated maximum levels of UHC effective coverage index 
achieved given any amount of health spending per 
capita—and compared country-level UHC effective 
coverage performance relative to these frontiers. The 
magnitude of these gaps between the frontier and UHC 
effective coverage index values provides insights into 
potential inefficiencies, as well as measurement error, in 
translating health spending into improved UHC effective 
coverage at the population level. Further analytical details 
are in the appendix 1 (pp 53–59).
Since UHC aims to minimise financial hardship 
associated with receiving essential health services, we 
focused on assessing the relationship between pooled 
health spending per capita (ie, government spending, 
prepaid private health spending, and development 
assistance for health)56 and UHC effective coverage 
performance. Alternative analyses, wherein out-of-pocket 
spending was included (ie, total health expenditure) and 
then development assistance for health was excluded 
(ie, pooled domestic health expenditures), were also done 
but are not reported here (appendix 2 pp 6–7).
Counting population equivalents with UHC effective 
coverage
Spurred by the GPW13 UHC billion target,6 which 
calls for 1 billion more people benefiting from UHC 
by 2023, various approaches have been considered 
for translating performance metrics into the number 
of people covered by health services.20,21,57,58 For this 
analysis, we used a similar approach currently recom-
mended by WHO:58 we applied index estimates as 
fractional metrics and multiplied these values by 
populations to approxi mate population equivalents 
with UHC effective coverage.
To assess UHC effective coverage trajectories and 
their contributions towards meeting the UHC 1 billion 
target, we first projected country-level UHC effective 
coverage index estimates through to 2023. These 
projections were based on stochastic frontier meta-
regression modelled relationships between UHC 
effective coverage index and total health spending per 
capita; a related method has been used previously by 
GBD26,59 and is described further in the appendix 1 
(pp 60–61). Taking UHC effective coverage index as a 
fraction, we multiplied these values by country-level 
GBD-based population forecasts through to 2023.60 
Last, we aggregated these estimates globally and by 
GBD super-region, and calculated additional population 
equivalents with UHC effective coverage from 2018 (the 
GPW13 baseline) to 2023.
Uncertainty analysis
GBD aims to propagate sources of uncertainty through 
its estimation process,34–36 resulting in 1000 draws 
from the posterior distribution for each measure by 
location, age, sex, and year. We incorporated uncertainty 
quantified for each effective coverage indicator and 
associated disease burden based on GBD 2019 esti-
mates, and did scaling, index construction, and UHC 
effective coverage index projections at the draw-level to 
reflect uncertainty. We report 95% uncertainty intervals 
(95% UIs) based on the ordinal 25th and 975th draws 
for each measure.
Source Content validity 
(proportion of 
cells covered)
Known-groups validity 
(proportion of 16 country 
pairs)
Convergent validity (variation of HALE 
explained, accounting for SDI)
Based on mean 
values
With 
uncertainty
Beta 
coefficient
Standard 
error
R2
UHC effective coverage index, health 
gains weighted (reported 2019)
GBD 2019 40% 94% 63% 5·00 1·72 0·073
UHC effective coverage index, 
unweighted average (reported 2019)
GBD 2019 40% 94% 56% 4·19 1·49 0·068
UHC service coverage index for SDGs 
(reported 2017)
GBD 2017 33% 94% 69% 4·30 1·76 0·053
UHC service coverage index for SDG 
indicator 3.8.1 (reported 2017)
WHO 2019 20% 75% ·· 4·21 1·88 0·044
Service coverage index (for most recent 
year reported)
World Bank 
2020
17% 56% ·· 1·24 1·18 0·010
Content validity was evaluated on the basis of the percentage of 30 matrix cells of health service types against population-age groups covered by each index. 
Known-groups validity was evaluated on the basis of the percentage of 16 country pairs correctly ranked based on country A’s UHC or health-system performance 
being recognised as better than country B’s performance; details are found in appendix 1 (pp 45–47). Convergent validity was evaluated on the basis of how much 
index performance could explain variation in HALE after controlling for levels of sociodemographic development (as measured by SDI). UHC=Universal health 
coverage. HALE=healthy life expectancy. SDI=Socio-demographic Index. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDGs=UN Sustainable 
Development Goals.
Table 2: Results for content, known-groups, and construct validity across multi-country health service indices for UHC service coverage measurement
See Online for appendix 2
Global Health Metrics
www.thelancet.com   Vol 396   October 17, 2020 1259
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
National UHC effective coverage patterns in 2019
In 2019, UHC effective coverage performance showed 
some strong geographical patterns (figure 3), but sizeable 
heterogeneities also emerged. Various European coun-
tries, including Iceland, as well as Australia, Canada, 
Japan, Singapore, and South Korea, comprised the highest 
decile, followed by a more geographically diverse group in 
the ninth decile (eg, Costa Rica, Israel, New Zealand, 
Portugal, and the USA). Sub-Saharan Africa had among 
the widest range of UHC effective coverage performances 
in 2019, with two countries ranking in the sixth decile 
(Rwanda and South Africa) and 11 countries in the first 
decile; the countries in the first decile were mainly in 
western or central sub-Saharan Africa, but also spanned 
the continent (eg, Angola, Lesotho, Madagascar, and 
Somalia). Outside of sub-Saharan Africa, ten countries, 
including Afghanistan, Haiti, Pakistan, and Papua New 
Guinea, were also in the lowest decile in 2019. In east, 
southeast, and south Asia, countries largely fell between 
the eighth (China and Thailand) and second deciles 
(Laos), with India and Indonesia occupying the third 
decile. Within Latin America, various countries scored in 
the eighth or seventh deciles (eg, Chile, Colombia, Peru, 
and Brazil) but others saw UHC effective coverage index 
values within the fourth to fifth deciles (eg, Bolivia, 
Guatemala, and Nicaragua).
Performance on the overall UHC effective coverage 
index often corresponded with levels achieved across 
individual effective coverage indicators (figure 4); for 
instance, countries with effective coverage index values 
of 85 or higher generally had the vast majority of effec-
tive coverage indicators exceeding 80. Although high-
performing locations usually had lower values for at least 
some subsets of indicators (eg, met need for family 
planning or antiretroviral therapy coverage), such indi-
cators often represented areas of lower potential health 
gains—especially relative to effective coverage indicators 
proxying health services or interventions for conditions 
with higher potential health gains in these countries 
(eg, cardiovascular diseases, cancers, and diabetes). 
Countries and territories with fairly low overall UHC 
effective coverage index performance in 2019 (ie, <40) 
scored similarly low across most effective coverage 
indicators, although vaccine coverage and proxies for 
lower respiratory infection and diarrhoea treatment were 
among the main exceptions.
Figure 3: Map of the UHC effective coverage index, by decile, in 2019
Deciles are based on the distribution of UHC effective coverage index values in 2019. UHC=universal health coverage.
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Many countries with middle-range performance on 
UHC effective coverage (ie, about 45–70) in 2019 had a 
mixture of fairly high values on most indicators for 
communicable diseases and reproductive, neonatal, 
maternal, and child health but comparatively lower 
scores on many non-communicable diseases, likely 
mirroring their variable epidemiological profiles and 
thus populations’ health needs. For some countries, 
especially those in sub-Saharan Africa (eg, Namibia, 
Rwanda, and Kenya), communicable diseases (eg, HIV) 
and reproductive, neonatal, maternal, and child health 
still ranked among indicators with highest potential 
health gains in 2019, even though non-communicable 
diseases such as cardiovascular diseases and diabetes are 
on the rise.35 With their fairly high levels of coverage or 
services proxied by effective coverage indicators for 
communicable diseases and for reproductive, neonatal, 
maternal, and child health, several of these countries had 
higher UHC effective coverage index performance under 
a health gains weighting approach than under the 
assumption that each effective coverage indicator could 
deliver equal health gains to populations across different 
settings (figure 2). By contrast, in many other countries—
especially those in Latin America, central and eastern 
Europe, and Oceania—non-communicable diseases 
accounted for a greater proportion of potential health 
gains by 2019; consequently, these countries’ relatively 
poor performances on several effective coverage indi-
cators proxying non-communicable disease services 
underpinned lower overall UHC effective coverage index 
values. High levels of vaccine coverage and performance 
on effective coverage indicators such as maternal care 
still contributed to UHC effective coverage performance 
for such countries; however, these health areas generally 
Figure 4: Performance on the UHC effective coverage index and 23 effective coverage indicators, by location, in 2019
Locations are reported in alphabetical order. The UHC effective coverage index and individual effective coverage indicators are reported on a scale of 0–100. 
Four indicators (met need for family planning, MCV1 coverage, DTP3 coverage, and ART coverage) are based on intervention coverage, whereas the remaining 
effective coverage indicators use measures such as mortality-to-incidence ratios to approximate access to quality care; inputs and measurement approaches for each 
indicator and index are further described in appendix 1 (pp 30–32). ART=antiretroviral therapy. CKD=chronic kidney disease. COPD=chronic obstructive pulmonary 
disease. DTP3=diphtheria, tetanus, pertussis vaccine, 3 doses. IHD=ischaemic heart disease. LRI=lower respiratory infection. MCV1=measles-containing vaccine, 
1 dose. TB=tuberculosis. UHC=universal health coverage.
19 11 685 948283 92 49 22 76 2139 1624 24 13 5915 24 22342554Zimbabwe
21 25 564 819394 79 62 51 71 4861 2526 26 17 4615 16 47152853Zambia
19 21 643 566672 85 85 73 84 7828 3138 30 35 4521 57 40394149Yemen
53 66 2076 588591 100 88 80 96 9456 4463 56 41 6157 34 74266960Vietnam
48 32 2276 825656 97 92 80 89 8547 6079 62 31 6264 43 66577761Venezuela
40 30 753 325145 96 78 46 64 585 1324 31 15 119 28 35303734Vanuatu
43 54 1583 789491 99 33 66 95 925 6861 53 38 5944 27 3397542Uzbekistan
64 61 3772 669097 99 97 89 96 7887 6167 70 45 6957 53 62587369Uruguay
70 59 6181 869393 100 99 88 97 9973 6899 82 49 7298 72 889710082USA
66 61 2087 636167 100 99 82 89 8023 6974 51 30 7263 42 77567254Virgin Islands
83 88 9989 859693 100 99 97 98 9588 6494 86 85 8194 100 66729488UK
83 67 1778 519692 100 100 89 95 9656 5460 43 19 5049 49 68767463United Arab Emirates
64 64 4567 507298 100 97 82 96 932 8562 62 87 6959 74 51317657Ukraine
15 25 652 777980 90 78 45 71 6357 3423 23 25 4514 24 53382453Uganda
56 33 847 196367 99 86 69 79 7817 3040 48 13 3128 18 39285740Tuvalu
35 46 1476 5110094 95 46 58 94 9117 5762 55 35 6744 40 48227344Turkmenistan
46 56 4763 449897 99 96 96 99 9361 7279 66 49 6766 57 65718469Turkey
62 53 4673 529694 100 97 95 98 9839 5778 69 50 7762 79 67608468Tunisia
46 48 1357 837790 99 94 74 92 7947 4269 48 24 6757 24 56605956Trinidad and Tobago
U
H
C 
eff
ec
ti
ve
 co
ve
ra
ge
 in
de
x
M
et
 n
ee
d 
fo
r f
am
ily
 p
la
nn
in
g 
w
ith
 m
od
er
n 
co
nt
ra
ce
pt
io
n
An
te
na
ta
l, 
pe
rip
ar
tu
m
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r n
ew
bo
rn
 b
ab
ie
s
An
te
na
ta
l, 
po
st
pa
rt
um
, 
an
d 
po
st
na
ta
l c
ar
e 
fo
r m
ot
he
rs
M
CV
1 
co
ve
ra
ge
DT
P3
 co
ve
ra
ge
Di
ar
rh
oe
a 
tr
ea
tm
en
t
LR
I t
re
at
m
en
t
AR
T 
co
ve
ra
ge
TB
 tr
ea
tm
en
t
Ac
ut
e 
ly
m
ph
oi
d 
le
uk
ae
m
ia
 tr
ea
tm
en
t
Br
ea
st
 ca
nc
er
 tr
ea
tm
en
t
Ce
rv
ica
l c
an
ce
r t
re
at
m
en
t
Ut
er
in
e 
ca
nc
er
 tr
ea
tm
en
t
Co
lo
n 
an
d 
re
ct
um
 ca
nc
er
 tr
ea
tm
en
t
IH
D 
tr
ea
tm
en
t
St
ro
ke
 tr
ea
tm
en
t
Di
ab
et
es
 tr
ea
tm
en
t
CK
D 
tr
ea
tm
en
t
CO
PD
 tr
ea
tm
en
t
As
th
m
a 
tr
ea
tm
en
t
Ep
ile
ps
y 
tr
ea
tm
en
t
Ap
pe
nd
ici
tis
 tr
ea
tm
en
t
Pa
ra
ly
tic
 il
eu
s a
nd
 in
te
st
in
al
ob
st
ru
ct
io
n 
tr
ea
tm
en
t
0
25
50
75
100
Index value
Global Health Metrics
1266 www.thelancet.com   Vol 396   October 17, 2020
represented a smaller fraction of population-level health 
gains than many non-communicable diseases in these 
settings. Health gain weights, by country and territory, 
for each effective coverage indicator are available in the 
appendix 2 (pp 11–13) and via online data tools.
Pace of progress on UHC effective coverage
Since 1990, UHC effective coverage performance 
improved, albeit at variable rates of progress over time 
and across GBD super-regions (figure 5). The global 
average increased from 45·8 (95% UI 44·2–47·5) in 1990 
to 60·3 (58·7–61·9) in 2019, while the absolute range in 
performance essentially remained the same (ie, 73·0-point 
difference in 1990 vs 74·0-point difference in 2019). 
By 2019, the UHC effective coverage index spanned 
from 95 or higher in Japan (96·3 [95·0–97·4]) and 
Iceland (95·3 [93·6–96·8]) to lower than 25 in the 
Central African Republic (22·3 [16·3–29·3]) and Somalia 
(23·9 [17·1–31·1]; appendix 2 pp 14–20). Globally, the pace 
of progress on UHC effec tive coverage was somewhat 
slower, albeit not significantly, from 2010 to 2019 (0·9% 
[0·6–1·2] annualised increase) than from 1990 to 2010 
(1·0% [0·8–1·1] annualised increase). Similarly, at the 
global level, annualised rates of change for population 
equivalents with effective coverage were slightly lower 
from 2010 to 2019 (2·0% [1·7–2·3]) than from 1990 to 2010 
(2·3% [2·2–2·4]), although this difference was not 
significant. However, some of these patterns diverged by 
GBD super-region (figure 5), as well as at the country 
level (appendix 2, pp 14–20). For instance, in sub-Saharan 
Africa, UHC effective coverage index performance 
improved at an average of 2·6% (1·9–3·3) per year 
from 2010 to 2019, surpassing its annualised rate of 
change from 1990 to 2010 (1·3% [1·0–1·7] average 
increase per year). Central Europe, eastern Europe, and 
central Asia also had significantly faster progress from 
2010 to 2019 (1·4% [0·8–1·8] average annual increase) 
than from 1990 to 2010 (0·5% [0·4–0·6] annual increase).
Relationship between health expenditure and UHC 
effective coverage
Country-level performance on UHC effective coverage 
widely varied across different levels of pooled health 
spending per capita (figure 6), highlighting how increased 
health spending is necessary but insufficient on its own 
to improve UHC effective coverage. Overall, the UHC 
effective coverage index was associated with pooled 
health spending per capita (r=0·79), but this relationship 
was varied at different levels of spending. Up to about 
$2500 (US$, adjusted for purchasing power parity) in 
pooled health spending per capita, increasingly higher 
expenditures generally paralleled higher performance 
on UHC effective coverage index; beyond that, higher 
expenditures did not correspond as consistently with 
further improvements in UHC effective coverage 
performance.
The UHC effective coverage frontier charts the highest 
UHC effective coverage performances, as achieved by 
countries in 2019, across different levels of pooled health 
spending per capita (figure 6); in other words, this frontier 
represents the relative efficiency—or ineffi ciency—with 
which countries could translate their health spending 
into improved UHC effective coverage. Countries 
including South Korea, Cyprus, Costa Rica, Peru, and 
Figure 5: Annualised rate of change in the UHC effective coverage index (A) and population equivalents with UHC effective coverage (B), globally and by GBD 
super-region, 1990–2010 and 2010–2019
Values reflect the average annualised rate of change on the UHC effective coverage index and population equivalents with UHC effective coverage between each time 
period. Population equivalents are based on taking the UHC effective coverage index as a fraction and multiplying these values by the total population for a given 
location-year to approximate populations covered with UHC effective coverage. UHC=universal health coverage. GBD=Global Burden of Diseases, Injuries, and Risk 
Factors Study.
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For more on the online data 
tools see http://ghdx.healthdata.
org/gbd-2019
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Rwanda were among those setting this performance 
frontier at their corresponding levels of pooled health 
expenditure per capita. Conversely, countries across 
the sociodemographic spectrum (ie, Central African 
Republic, Lesotho, Turkmenistan, Saudi Arabia, and 
the USA) showed large gaps between their estimated 
UHC effective coverage index perfor mances in 2019 and 
what could have been achievable on the UHC effective 
coverage frontier given these countries’ levels of pooled 
health spending. To reach a UHC effective coverage index 
of at least 80, under maximum efficiency, countries would 
need to reach US$1398 in pooled health spending per 
capita (per year). Equivalent analyses and figures for 
total health expendi ture per capita (ie, pooled health 
spending plus out-of-pocket spending) and pooled 
domestic health expenditure per capita (ie, pooled health 
spending minus development assistance for health) are 
provided in appendix 2 (pp 6–7).
Counting population equivalents with effective 
coverage for the UHC billion target 
Based on current projections, an estimated 5·0 billion 
(95% UI 4·8–5·1) population equivalents would have UHC 
effective coverage in 2023 (table 3). This would translate to 
388·9 million (358·6–421·3) more population equivalents 
with UHC effective coverage over the five-year GPW13 
evaluation period (2019–23, with 2018 as the baseline), or 
the equivalent of adding an average of 77·8 million 
(71·7–84·3) population equivalents per year during this 
time. From 2018 to 2023, sub-Saharan Africa was estimated 
to contribute the most additional population equivalents 
with UHC effective coverage (ie, 94·5 million [83·6–104·8]). 
By 2023, an estimated 3·1 billion (3·0–3·2) population 
equivalents would not have UHC effective coverage, with 
nearly a third residing in south Asia (ie, an estimated 
968·1 million [903·5–1040·3]).
Discussion
Summary of the main findings
The present study offers a new approach to monitoring 
progress on UHC service coverage: measuring country-
level effective coverage and thus better representing how 
well health systems are delivering health gains relative to 
their populations’ health needs. Amid global advances 
on the UHC effective coverage index since 1990, our 
findings show a gap of more than 70 points between 
locations with the highest and lowest levels of UHC 
effective coverage remained in 2019. Particularly among 
low-middle to middle-SDI countries, performance of 
effective coverage indicators for non-communicable 
diseases was far lower than levels reached for several 
communicable diseases and maternal and child health 
indicators—a pattern suggesting that many countries’ 
health systems and financing priorities are not moving 
as quickly as their epidemiological and demographic 
transitions. Higher pooled health spending per capita 
generally corresponded with higher UHC effective 
Figure 6: UHC effective coverage index frontier relative to pooled health spending per capita (A) and 
log-transformed pooled health spending per capita (B)
Pooled health spending per capita includes government health expenditures, prepaid private expenditures, and 
development assistance for health. All health spending estimates are for 2017 measured in 2019 PPP-adjusted 
US$ adjusted for inflation. The black line represents the frontier values estimated for UHC effective coverage in 
2019 relative to spending per capita in 2017. Locations are colour-coded by GBD super-region, with a subset 
abbreviated according to their ISO3 codes. ISO3 codes and corresponding location names are listed in appendix 1 
(pp 64–68). UHC=universal health coverage. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. 
PPP=purchasing-power parity.
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coverage. Nonetheless, country-level performance varied 
widely and many countries fell well below levels achieved 
by other countries with similar amounts of health 
expenditures, emphasising the importance of increasing 
both health-system efficiencies and funding for UHC. 
To achieve at least 80 on the UHC effective coverage 
index, countries would need to reach $1398 pooled 
spending per capita—and do so under maximum 
efficiency. An estimated 388·9 million more population 
equivalents would have UHC effective coverage between 
2018 and 2023, falling well short of the GPW13 target of 
1 billion more people benefiting from UHC during this 
time. Genuinely advancing toward UHC requires 
prioritising—and thus monitoring—effective coverage 
and health systems’ capacities for improving outcomes 
for all people throughout the world.
Past progress, current challenges, and accelerating 
future gains on UHC effective coverage
By 2019, UHC effective coverage improved substan tially 
for many countries, and for some countries the pace of 
progress has accelerated since 2010. This was particularly 
evident in sub-Saharan Africa; this GBD super-region 
nearly doubled its average annual improve ments from 
2010 to 2019 compared to 1990–2010. Such gains could be 
related to heightened funding—and thus prioritisation—
for HIV, vaccines and childhood infectious diseases, and 
maternal health during the Millennium Development 
Goal (MDG) era.61,62 As further illustrated by the UHC 
effective coverage frontier, up to about $2500 per capita, 
rising levels of UHC effective coverage index generally 
paralleled pooled health spending; this trend highlights 
the important role of increasing funding for UHC to 
jumpstart progress, particularly for countries that still 
have very low UHC effective coverage in 2019. Yet even 
at the frontier, reaching better UHC effective coverage 
performance requires much higher pooled health 
spending per year: an estimated $1398 per capita to reach 
80, and then $2538 per capita to reach 90 and $3424 per 
capita to reach 95. At present, the only countries 
achieving 90 or higher on the UHC effective coverage 
index and such levels of pooled health spending per 
capita are within the high-income GBD super-region. 
Substantially increasing total health spending could be 
one avenue for elevating UHC effective coverage 
performance; however, many countries still have high 
out-of-pocket spending relative to their total spending,56,61 
which is strongly related to household catastrophic 
health expenditures and directly counter to improving 
financial risk protection within UHC. Focusing on 
domestic heath spending while also elevating efficiency 
could be another viable route; our results show that many 
countries would theoretically achieve much higher UHC 
effective coverage if they could better translate current 
amounts of pooled spending per capita into improved 
performance. How to best address such inefficiencies 
will markedly vary across contexts, and will require 
accounting for country-level differences in health-sys-
tem orientations and structures, political stability and 
governance systems, and distribution of health resources 
among populations. Further examination of approaches 
used by countries near or at the UHC effective coverage 
frontier relative to their pooled health spending (eg, 
Rwanda, Peru, South Korea, and Costa Rica) might help 
identify tractable policy pathways to improved efficiency.
Poor performance on various non-communicable 
diseases has severely hindered progress on UHC 
effective coverage in many countries—a trend that is 
likely to only worsen until quality health services for 
non-communicable diseases are better prioritised by 
countries and development partners alike. Especially 
among low-middle SDI to middle-SDI countries, earlier 
advances on UHC effective coverage were mainly 
propelled by improving health services focused on 
communicable diseases, child health, and maternal care. 
As cardiovascular disease, diabetes, cancers, and other 
UHC effective coverage index (95% UIs) Population equivalents with UHC effective coverage (95% UI)*
2018 2023 Added from 2018–23 Covered in 2023 Not covered in 2023
Global 59·8 (58·3 to 61·3) 61·7 (60·1 to 63·3) 388·9 (358·6 to 421·3) 5·0 billion (4·8 to 5·1) 3·1 billion (3·0 to 3·2)
Central Europe, eastern 
Europe, and central Asia
63·2 (61·0 to 65·5) 65·2 (62·7 to 67·6) 9·1 (7·5 to 10·9) 273·0 (262·5 to 282·8) 145·5 (135·7 to 156·1)
High income 85·8 (84·3 to 87·1) 87·1 (85·5 to 88·5) 31·6 (28·8 to 34·3) 958·3 (940·7 to 972·8) 141·5 (127·0 to 159·1)
Latin America and Caribbean 63·2 (61·1 to 65·1) 65·6 (63·3 to 67·8) 33·6 (30·8 to 36·5) 398·5 (384·7 to 412·0) 209·0 (195·6 to 222·8)
North Africa and Middle East 60·0 (57·9 to 61·9) 61·9 (59·6 to 64·0) 43·0 (39·8 to 45·9) 402·3 (387·6 to 416·1) 247·8 (233·9 to 262·5)
South Asia 46·0 (42·6 to 49·2) 48·4 (44·6 to 51·9) 88·9 (73·5 to 102·8) 909·4 (837·2 to 974·0) 968·1 (903·5 to 1040·3)
Southeast Asia, east Asia, and 
Oceania
64·2 (60·7 to 67·6) 66·9 (63·0 to 70·5) 88·2 (74·4 to 102·8) 1·5 billion (1·4 to 1·5) 726·3 (647·9 to 811·6)
Sub-Saharan Africa 43·9 (41·4 to 46·5) 46·2 (43·3 to 49·1) 94·5 (83·6 to 104·8) 555·6 (521·1 to 590·1) 647·1 (612·7 to 681·7)
Population equivalents based on taking the UHC effective coverage index as a fraction and multiplying these values by total population for a given location-year to approximate 
populations covered with UHC effective coverage. UHC=universal health coverage. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. 95% UI=95% uncertainty 
interval. *Reported in millions unless otherwise indicated.
Table 3: Projected UHC effective coverage performance in 2023 and additional population equivalents with UHC effective coverage from 2018 to 2023, 
globally and by GBD super-region
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non-communicable diseases became leading causes of 
early death and disability, they also emerged as population 
health needs with the highest potential health gains—
that is, where health systems could increasingly deliver 
the most improved outcomes via effective coverage of 
interventions and services. Re-orienting countries’ health 
systems towards providing effective health services for 
non-communicable disease is not trivial, especially if 
their prior focus (and funding) had a more limited 
scope for the types of services provided, equipment 
used, and health workforce training required. However, 
continued inaction also has likely costs: if health 
systems remain too focused on health problems of the 
past, and fail to effectively respond to where the largest 
potential health gains exist today, it can be increasingly 
difficult to translate current levels of health spending 
into improved UHC effective coverage. For instance, 
only a few high-SDI countries (eg, Japan, Switzerland, 
and South Korea) averaged non-communicable disease 
performance equal to or higher than effective coverage 
indicators focused on communicable diseases and 
maternal and child health by 2019.63 Unless deliberate 
efforts are taken now to recalibrate health-system and 
funding priorities, the ability to alter current trajectories 
for UHC effective coverage could diminish.
To catalyse faster gains in the SDG era, WHO’s 
GPW13 set forth its bold billion targets,6 with the UHC 
target calling for 1 billion more people benefiting from 
UHC by 2023, relative to 2018. Current projections have 
the world falling well short of this ambition, with an 
estimated 388·9 million (358·6–421·3) more population 
equivalents having UHC effective coverage by 2023. 
Even these estimates are likely to be optimistic, as they 
do not account for trends in financial risk protection—
the other key dimension of UHC—nor do they explicitly 
account for populations’ needs for multiple health 
services. Nonetheless, this initial assessment offers 
important considerations for the remaining years of 
GPW13 and then through to 2030. With more than 
3 billion popu lation equivalents estimated to lack UHC 
effective coverage in 2023, targeting populous regions 
or countries that currently have low UHC effective 
coverage and investing in service expansion could be 
one option to accelerating future progress. For instance, 
south Asia, in combination with southeast Asia, east 
Asia, and Oceania, was estimated to have nearly 
1·7 billion population equivalents without UHC 
effective coverage in 2023. However, on the basis of 
current levels of health spending, many countries in 
these regions already fell below their potential UHC 
effective coverage perfor mance in 2019. For most 
countries, heightened health spending alone is unlikely 
to deliver on ambitious UHC targets; rather, a com-
bination of improving alignment of health systems 
with population health needs and bolstering efficiencies 
is likely to chart faster and perhaps more sustained 
gains.
Current challenges and future directions for measuring 
UHC effective coverage
Our measurement framework is grounded in the 
construct of effective coverage at the health-system level,16 
aiming to represent a country’s ability to improve health 
outcomes in accordance with the health needs and disease 
burden of its population. From this perspective, effec-
tive coverage should capture the fraction of potential 
population-level health gains actually delivered by the 
health system, relative to what the health system could 
have provided at maximum performance of current 
interventions or services. As such, we used health gain 
weights to construct the overall UHC effective coverage 
index and to more heavily weight effective coverage 
indicators for which a given country’s health could 
produce greater health gains through available interven-
tions. By contrast, the unweighted average of effective 
coverage indicators implies equal potential health gains 
irrespective of a country’s epidemiological profile or 
effectiveness of the associated interventions or ser vices, or 
a combination of both. Equally weighting interventions 
and their potential for improving health is directly counter 
to the reality of UHC programmes, which are subject to 
each country’s unique health-system structures, political 
demands, and health priorities. To capture what can—or 
should—be achievable through health systems’ provision 
of effective services, we believe the health gains weighting 
approach can better track country-led UHC investments 
and policy implementation. Going forward, assessments 
of UHC effective coverage should strive to apply this 
method beyond the national level, aiming to capture 
inequalities in potential health gains not only by location 
but also within population-age groups, by sex, and across 
other important sociodemographic dimensions (eg, race/
ethnicity and migrant status).
Routinely measuring UHC effective coverage requires 
the existence and maintenance of several functional data 
systems. Many, if not most, indicators or data systems, or 
both, that are needed to measure effective coverage 
indicators are already encompassed within the health-
related SDGs, which UN member states have committed 
to monitoring. These include functional vital registration 
systems that accurately record causes of death; periodic 
household surveys that include biomarker data and 
information on intervention coverage; and disease 
incidence registries based on administrative systems and 
notifications for specific causes (eg, cancers and kidney 
disease).64 Deliberate investments by national govern-
ments, as well as international agencies where appropriate, 
are important for strengthening these data systems and 
identifying how they can be used together to monitor 
trends in effective coverage.
The UHC effective coverage index and corresponding 
UHC effective coverage measurement framework repre-
sent important steps towards capturing a range of needed 
health services across the life course; nonetheless, as 
underscored by its multi-year development process 
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(appendix 1 pp 6–21), considerable gaps persist between 
the breadth of the original candidate effective coverage 
indicators and those used in the present analysis. Minimal 
data on rehabilitative services and palliation across 
countries and over time hindered their direct inclusion or 
the use of suitable proxy effective coverage indicators. 
Recent steps by WHO (ie, publishing its first world report 
on vision65 and upcoming report on hearing,66 and its 
GPW13 indicator on oral morphine availability6) suggest 
that data collection for these areas could be increasingly 
prioritised. A similar paucity of routinely collected data 
on mental health services and substance use disorder 
interventions precluded their use in the current UHC 
effective coverage index. In the future, triangulation of 
data sources including administrative records, health 
facility records, and community-based surveys might 
inform such mea surements.67 Effective coverage indi-
cators on emergency services and trauma care were also 
considered but ultimately excluded because of data 
limitations and ongoing methodological challenges 
(ie, appropriately isolating improvements in effective 
health services from advances in transportation safety).
For non-communicable diseases, we relied on out-
come-based effective coverage indicators, preferring to 
approxi mate access to quality non-communicable disease 
care through measures such as MIRs rather than 
assuming that risk exposure, screening rates, or health-
system inputs, or a combination of these factors, can 
appropriately capture effective service provision for non-
communicable diseases. Many national data systems 
already collect data on cause-specific mortality and 
disease incidence or prevalence, and when analysed 
together they should reflect variations in access to and 
quality of health services and serve as good proxy mea-
sures amid imperfect data realities for non-communicable 
disease services. Conversely, using indicators such as 
non-tobacco use and non-elevated blood pressure4,19,21 or 
inpatient admission rates pushes the world further away 
from understanding improved outcomes delivered by 
health systems and effective service provision. If, or 
when, the quantity and quality of data for measuring 
health services for non-communicable diseases improve, 
we would prefer to use more direct measures of 
effec tive coverage over outcome-based proxy indicators. 
For instance, our ideal effective coverage indicator for 
diabetes treatment would be the proportion of people 
with diabetes on treatment and meeting specified 
treatment targets such as glycated haemoglobin lower 
than 8%. Household surveys such as the WHO STEPwise 
approach to surveillance (STEPS) are increasingly col-
lecting these data, and time series estimates by location 
and population-age group could be easily derived if 
sufficient access to such microdata is possible.
In sum, the indicators included in the present study 
are not meant to be prescriptive; rather, our primary 
objective was to establish a robust, comparable measure-
ment framework from which UHC effective coverage 
could be assessed across settings and inform efforts to 
incorporate effective coverage into UHC monitoring. 
Continuing to advance effective coverage measurement 
of UHC in the future, especially if the main alternative is 
adhering to past measures with known drawbacks and 
narrow operationalisations of health services for all 
populations, is strongly supported by the broader GBD 
study and its collaborators.
Limitations
Our study is subject to limitations beyond those already 
described. First, this analysis draws from GBD 2019 
estimates of outcomes, intervention coverage, and SDG 
indicators,34–36 and thus broader GBD 2019 limitations 
also apply to the present study (eg, availability and quality 
of vital registration data, model coherence between 
cause-specific mortality and non-fatal measures, and 
new modelling approaches for risk factors and related 
outcomes). In the case of ischaemic heart disease, for 
example, new data on the interplay of household air 
pollution, blood pressure, and ischaemic heart disease 
mortality resulted in implausible risk-standardised death 
rates for many low-SDI to low-middle SDI countries 
when we only accounted for joint exposures to metabolic 
risks considered amenable to health care.41,43 We thus 
included household and outdoor air pollution in risk 
standardisation and plan to further examine these risk 
mediation pathways in the future.
Second, health gain weights were based on classifying 
intervention sets into five effectiveness categories, as 
informed by published literature provided by Cochrane, 
the Tufts Cost-Effectiveness Analysis Registry, and 
DCP3.For some effective coverage indicators, especially 
treat ment of more chronic conditions, distilling a wide 
range of reported effectiveness on available interven-
tions into a summary assessment was quite difficult. 
Sensitivity analyses based on shifting each indicator’s 
categorisation up and down one group showed similar 
overall UHC effective coverage index values (appendix 1 
p 35). Formally simulating the range of effectiveness 
across interventions and incorporating this uncertainty 
into health gains weighting is an important future 
avenue for measurement of the UHC effective coverage 
index.
Third, due to limited data quantity or quality (or both), 
we could not include several original candidates for 
effective coverage indicators (appendix 1 pp 12–28), 
including seven expressly recommended by the GPW13 
ERG: HPV vaccination, hepatitis C treatment, effective 
management of hypertension and diabetes, cataract 
surgery, refractive error correction, and dental care.33 
As data availability improves alongside methods for 
estimating these indicators across countries, we plan to 
test the inclusion of these indicators, and thus some 
country-level UHC effective coverage index values and 
rankings might change. Since data are generally more 
easily available for better-funded interventions and health 
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areas, it is possible that our current estimates of UHC 
effective coverage are overly optimistic.
Fourth, we excluded several effective coverage indi-
cators for which high potential health gains could only be 
achieved in select locations because of local exposures 
(ie, malaria and neglected tropical diseases) or current 
introduction status (eg, pneumococcal conjugate vaccine 
[PCV]). Subsequently, our results might under-estimate 
UHC effective coverage in some locations (eg, countries 
with high coverage of effective malaria interventions) or 
over-estimate performance in others (eg, countries that 
have a high pneumonia burden but have yet to introduce 
PCV). Additional methodological testing is needed to 
better incorporate these locally relevant intervention 
needs within a global measurement framework.
Fifth, we did not explicitly account for the effects 
of potential community-level interventions and their 
contribution to potential health gains (eg, herd immunity 
garnered from very high coverage of MCV1 or DTP3). 
Future work should consider whether or how such effects 
can be incorporated into this measurement framework, 
particularly given the toll of recent measles outbreaks 
worldwide.68
Sixth, results of our known-groups validity testing might 
have varied if more or different country-pairs were selected 
(appendix 1 pp 45–47). Showing performance based on 
country means and uncertainty underscores the need to 
further strengthen data collection and overarching mea-
surement for UHC effective coverage at the country level. 
Furthermore, it stresses the importance of estimating and 
reporting uncertainty in monitoring UHC, a limitation of 
current WHO and World Bank service coverage indices.
Seventh, approximating populations with UHC effec-
tive coverage by assuming the UHC effective coverage 
index as a fractional metric and multiplying by popula-
tion does not account for multimorbidities, nor does it 
represent the distribution of needed services received 
within a given population. Measuring UHC effective 
coverage at increasing granularity (ie, subnational loca-
tions and by disaggregated age groups or sex, or both) 
could help improve our understanding of the distribution 
of health services within a given population.
Conclusion
This study provides a new measurement framework and 
metric on UHC effective coverage, supporting country 
and global stakeholders in their efforts to track improved 
performance over time. By striving to capture potential 
health gains delivered by health systems, we hope to 
better diagnose and address challenges that otherwise 
impede the ultimate objective of UHC: improving health 
for all people and leaving no one behind. If current 
trends hold, the world will fall short of delivering on its 
UHC ambitions for the GPW13 and SDGs. Although this 
outcome is not yet inevitable, the window for meaningful 
action and health-system changes is rapidly narrowing. 
By focusing on UHC effective coverage and populations’ 
health needs across the lifespan, we strengthen the 
evidence base for bringing UHC closer to reality for all.
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Pharmaceutics Research Center (K Eskandari PhD), HIV/STI 
Surveillance Research Center, and WHO Collaborating Center for HIV 
Surveillance (Prof H Sharifi PhD), Health Services Management 
Research Center (V Yazdi-Feyzabadi PhD), Department of Health 
Management, Policy, and Economics (V Yazdi-Feyzabadi PhD), Kerman 
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(C S e Farinha MSc), Directorate-General of Health (DGS), Lisbon, 
Portugal; Department of Medical and Surgical Sciences (A Farioli PhD, 
Prof F S Violante MD), University of Bologna, Bologna, Italy; 
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University of KwaZulu-Natal, Durban, South Africa 
(Prof F C Tanser PhD); Department of Pediatrics 
(M Gitimoghaddam MD), School of Population and Public Health 
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(S V Gopalani MPH), Government of the Federated States of Micronesia, 
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Earth Observation Science (P Jia PhD), University of Twente, Enschede, 
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System Sciences (S M Karimi PhD), University of Louisville, Louisville, 
KY, USA; Center for Health Equity (S M Karimi PhD), Louisville Metro 
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MRC/CSO Social and Public Health Sciences Unit (S V Katikireddi PhD), 
University of Glasgow, Glasgow, UK; International Research Center of 
Excellence (G A Kayode PhD), Institute of Human Virology Nigeria, 
Abuja, Nigeria; Julius Centre for Health Sciences and Primary Care 
(G A Kayode PhD), Utrecht University, Utrecht, Netherlands; Open, 
Distance and eLearning Campus (Prof P N Keiyoro PhD), Department of 
Psychiatry (M Kumar PhD), School of Economics (M K Muriithi PhD), 
School of Public Health (R G Wamai PhD), University of Nairobi, 
Nairobi, Kenya; Department of Public Health (Prof Y S Khader PhD), 
Jordan University of Science and Technology, Irbid, Jordan; Department 
of Epidemiology and Biostatistics (E A Khan MPH), Health Services 
Academy, Islamabad, Pakistan; Department of Health Policy and 
Management (Prof Y Khang MD), Institute of Health Policy and 
Management (Prof Y Khang MD), Seoul National University, Seoul, 
South Korea; Faculty of Health and Wellbeing (K Khatab PhD), Sheffield 
Hallam University, Sheffield, UK; College of Arts and Sciences 
(K Khatab PhD), Ohio University, Zanesville, OH, USA; The Iranian 
Academy of Medical Sciences, Tehran, Iran (M Khayamzadeh MD); 
Department of Nutrition and Health Science (Prof J Khubchandani PhD), 
Ball State University, Muncie, IN, USA; Department of Preventive 
Medicine (Y Kim PhD), Korea University, Seoul, South Korea; School of 
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Malaysia, Sepang, Malaysia; Department of Nutrition 
(R W Kimokoti MD), Simmons University, Boston, MA, USA; Faculty of 
Health (Y Kinfu PhD), University of Canberra, Canberra, ACT, Australia; 
College of Medicine (Y Kinfu PhD), Qatar University, Doha, Qatar; 
School of Health Sciences (Prof A Kisa PhD), Kristiania University 
College, Oslo, Norway; Global Community Health and Behavioral 
Sciences (Prof A Kisa PhD), Tulane University, New Orleans, LA, USA; 
Department of Health Economics and Social Security 
(K Kissimova-Skarbek PhD), Jagiellonian University Medical College, 
Krakow, Poland; Department of Epidemiology and Public Health 
(Prof M Kivimäki PhD), Division of Psychology and Language Sciences 
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of Public Health (Prof M Kivimäki PhD), University of Helsinki, 
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Informatics of the Ministry of Health (FRIHOI), Moscow, Russia 
(A V Korotkova PhD); Independent Consultant, Jakarta, Indonesia 
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Institute for Global Health, Barcelona, Spain (Prof J V Lazarus PhD); 
School of Pharmacy (S W H Lee PhD), Monash University, Selangor, 
Malaysia; School of Pharmacy (S W H Lee PhD), Taylor’s University 
Lakeside Campus, Subang Jaya, Malaysia; Neurology, Public Health and 
Disability Unit (M Leonardi MD, A Raggi PhD, D Sattin PsyD, 
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Kuala Lumpur, Malaysia; Department of Medicine and Therapeutics 
(L Lim MRCP), The Chinese University of Hong Kong, Shatin, NT, 
China; Department of Systems, Populations, and Leadership 
(X Liu PhD), University of Michigan, Ann Arbor, MI, USA; Department 
of Basic Medical Sciences, Neuroscience and Sense Organs 
(Prof G Logroscino PhD), University of Bari Aldo Moro, Bari, Italy; 
Department of Clinical Research in Neurology (Prof G Logroscino PhD), 
Fondazione Cardinale Giovanni Panico Hospital, Tricase, Italy; Radiology 
and Precision Health Program (M Mahmoudi PhD), Michigan State 
University, East Lansing, MI, USA; Faculty of Medicine 
(J N Malagón-Rojas MSc), El Bosque University, Bogota, Colombia; 
Faculty of Public Health (S Martini PhD), Airlangga University, 
Surabaya, Indonesia; Indonesian Public Health Association, Surabaya, 
Indonesia (S Martini PhD); Campus Caucaia (F R Martins-Melo PhD), 
Federal Institute of Education, Science and Technology of Ceará, 
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(M R Mathur PhD), University of Liverpool, Liverpool, UK; Department 
of Ophthalmology (C McAlinden PhD), Singleton Hospital, Swansea, 
UK; Academic Area of Dentistry (C E Medina-Solís MSc), Autonomous 
University of Hidalgo State, Pachuca, Mexico; Department of Pharmacy 
(B Meharie MSc), Wollo University, Dessie, Ethiopia; Neurology 
Department (Prof M Mehndiratta MD), Janakpuri Super Specialty 
Hospital Society, New Delhi, India; Department of Neurology 
(Prof M Mehndiratta MD), Govind Ballabh Institute of Medical 
Education and Research, New Delhi, India; Department of Nutrition 
(T Mekonnen MPH), University of Oslo, Oslo, Norway; Institute of 
Human Virology (P T N Memiah DrPH), University of Maryland, 
Baltimore, MD, USA; Peru Country Office (W Mendoza MD), 
United Nations Population Fund (UNFPA), Lima, Peru; Neurology Unit 
(A Meretoja MD), Breast Surgery Unit (T J Meretoja MD), Helsinki 
University Hospital, Helsinki, Finland; Clinical Microbiology and 
Parasitology Unit (T Mestrovic PhD), Dr. Zora Profozic Polyclinic, 
Zagreb, Croatia; University Centre Varazdin (T Mestrovic PhD), 
University North, Varazdin, Croatia; Center for Innovation in Medical 
Education (B Miazgowski MD), Pomeranian Medical University, 
Szczecin, Poland (B Miazgowski MD); Department of Women-Mother-
Child (I Michalek PhD), Vaud University Hospital Center, Lausanne, 
Switzerland; Internal Medicine Programme 
(Prof E M Mirrakhimov PhD), Kyrgyz State Medical Academy, Bishkek, 
Kyrgyzstan; Department of Atherosclerosis and Coronary Heart Disease 
(Prof E M Mirrakhimov PhD), National Center of Cardiology and 
Internal Disease, Bishkek, Kyrgyzstan; Institute of Addiction Research 
(ISFF) (B Moazen MSc), Frankfurt University of Applied Sciences, 
Frankfurt, Germany; Department of Epidemiology and Biostatistics 
(A Mohammadian-Hafshejani PhD), Shahrekord University of Medical 
Sciences, Shahrekord, Iran; Department of Public Health 
(J A Mohammed MPH), Samara University, Semera, Ethiopia; Health 
Systems and Policy Research Unit (S Mohammed PhD), Department of 
Community Medicine (M B Sufiyan MD), Ahmadu Bello University, 
Zaria, Nigeria; Clinical Epidemiology and Public Health Research Unit 
(L Monasta DSc, L Ronfani PhD), Burlo Garofolo Institute for Maternal 
and Child Health, Trieste, Italy; Department of Biomedical and Dental 
Sciences and Morphofunctional Imaging (Prof S Mondello MD), 
Messina University, Messina, Italy; Department of Food Science 
(Prof A Mousavi Khaneghah PhD), University of Campinas (Unicamp), 
Campinas, Brazil; Department of Pediatric Medicine 
(Prof G Mustafa MD), The Children’s Hospital & The Institute of Child 
Health, Multan, Pakistan; Department of Pediatrics & Pediatric 
Pulmonology (Prof G Mustafa MD), Institute of Mother & Child Care, 
Multan, Pakistan; Knowledge Translation and Utilization Unit 
(Prof A F Nabhan PhD), Egyptian Center for Evidence Based Medicine, 
Cairo, Egypt; Research and Analytics Department 
(A J Nagarajan MTech), Initiative for Financing Health and Human 
Development, Chennai, India; Department of Research and Analytics 
(A J Nagarajan MTech), Bioinsilico Technologies, Chennai, India; 
Laboratory of Public Health Indicators Analysis and Health 
Digitalization (M Naimzada MD, N Otstavnov BA, S S Otstavnov PhD, 
M V Titova PhD), Moscow Institute of Physics and Technology, 
Dolgoprudny, Russia; Experimental Surgery and Oncology Laboratory 
(M Naimzada MD), Kursk State Medical University, Kursk, Russia; 
Suraj Eye Institute, Nagpur, India (V Nangia MD); Department for the 
Control of Disease, Epidemics, and Pandemics (J Nansseu MD), 
Ministry of Public Health, Yaoundé, Cameroon; Department of Public 
Heath (J Nansseu MD), Department of Public Health 
(G Nguefack-Tsague PhD), University of Yaoundé I, Yaoundé, 
Cameroon; Disease Control and Environmental Health (R Ndejjo MSc), 
Makerere University, Kampala, Uganda; Department of General Surgery 
(I Negoi PhD), Emergency Hospital of Bucharest, Bucharest, Romania; 
Cardio-Aid, Bucharest, Romania (R I Negoi PhD); Department of Health 
Sciences (S Neupane PhD), University of Tampere, Tampere, Finland; 
Research & Statistics Unit (K N Ngari MSc), Synotech Consultants, 
Nairobi, Kenya; Department of Biological Sciences (J W Ngunjiri DrPH), 
University of Embu, Embu, Kenya; Department of Health Policy and 
Management (S Nomura PhD), Keio University, Tokyo, Japan; 
Department of Global Health Policy (S Nomura PhD), University of 
Tokyo, Tokyo, Japan; Translational Health Research Institute 
(F A Ogbo PhD, Prof A M N Renzaho PhD), School of Social Sciences 
and Psychology (Prof A M N Renzaho PhD), Western Sydney University, 
Sydney, NSW, Australia; Department of Preventive Medicine (I Oh PhD), 
Kyung Hee University, Dongdaemun-gu, South Korea; Disease 
Surveillance and Epidemic Response (E W Okunga MSc), Ministry of 
Health, Nairobi, Kenya; Gorgan Congenital Malformations Research 
Center (M Oladnabi PhD), Golestan Research Center of 
Gastroenterology and Hepatology (GRCGH) (G Roshandel PhD), 
Golestan University of Medical Sciences, Gorgan, Iran; Department of 
Psychiatry (A T Olagunju MD), University of Lagos, Lagos, Nigeria; 
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(Prof O E Onwujekwe PhD), University of Nigeria Nsukka, Enugu, 
Nigeria; Department of Medicine (Prof A Ortiz MD), Princess University 
Hospital (Prof J B Soriano MD), Autonomous University of Madrid, 
Madrid, Spain; Department of Nephrology and Hypertension 
(Prof A Ortiz MD), The Institute for Health Research Foundation 
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Biomedical Sciences (Prof S M Ostojic PhD), University of Novi Sad, 
Novi Sad, Serbia; Department of Project Management 
(S S Otstavnov PhD), Department of Health Care Administration and 
Economics (Prof V Vlassov MD), National Research University Higher 
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Bergen, Norway; Department of Health Metrics (A Pana MD), Center for 
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of Health Research and Development (H U Pangaribuan MSc), Ministry 
of Health, Jakarta, Indonesia; Research & Development Department 
(M Pathak PhD), Kalinga Institute of Medical Sciences, Bhubaneswar, 
India; Population Health Theme (Prof G C Patton MD), Centre for 
Adolescent Health (Prof S M Sawyer MD), Critical Care and 
Neurosciences (Prof R G Weintraub MB), Murdoch Childrens Research 
Institute, Melbourne, VIC, Australia; Public Health Youth Society of 
Nepal, Pokhara, Nepal (S Paudel MPH); Public Health Update, Pokhara, 
Nepal (S Paudel MPH); College of Public Health, Medical, and 
Veterinary Sciences (A E Peden PhD), James Cook University, 
Townsville, NSW, Australia; School of Global Public Health 
(E K Peprah PhD), New York University, New York, NY, USA; 
Department of Orthopedics (J Pereira MS), Yenepoya Medical College, 
Mangalore, India; Department of Cardiology (T Pilgrim MD), University 
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(K N Pokhrel PhD), Integrated Development Foundation Nepal, 
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